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PLINICAL RESEARCH Clinical Trial
enal Toxicity Evaluation and
omparison Between Visipaque (Iodixanol)
nd Hexabrix (Ioxaglate) in Patients With Renal
nsufficiency Undergoing Coronary Angiography
he RECOVER Study: A Randomized Controlled Trial
ang-Ho Jo, MD,* Tae-Jin Youn, MD,* Bon-Kwon Koo, MD,* Jin-Shik Park, MD,* Hyun-Jae Kang, MD,*
oung-Seok Cho, MD,* Woo-Young Chung, MD,* Gwon-Wook Joo, MD,† In-Ho Chae, MD,*
ong-Ju Choi, MD,* Byung-Hee Oh, MD,* Myoung-Mook Lee, MD,‡ Young-Bae Park, MD,*
yo-Soo Kim, MD*
eoul and Gyeonggi-do, Korea
OBJECTIVES This study sought to compare the nephrotoxicity of iodixanol and ioxaglate in patients with
renal impairment undergoing coronary angiography.
BACKGROUND Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephro-
toxic than low-osmolar contrast media (LOCM) in high-risk patients.
METHODS In a prospective, randomized trial in 300 adults with creatinine clearance (CrCl)60 ml/min,
patients received either iodixanol or ioxaglate and underwent coronary angiography with or
without percutaneous coronary intervention. The primary end point was the incidence of
contrast-induced nephropathy (CIN) (an increase in serum creatinine [SCr] 25% or 0.5
mg/dl [44.2 mol/l]). The incidence of CIN in patients with severe renal impairment at
baseline (CrCl 30 ml/min) or diabetes and in those receiving large doses (140 ml) of
contrast medium was also determined.
RESULTS The incidence of CIN was significantly lower with iodixanol (7.9%) than with ioxaglate
(17.0%; p  0.021), corresponding to an odds ratio (OR) of CIN of 0.415 (95% confidence
interval [CI] 0.194 to 0.889) for iodixanol. The incidence of CIN was also significantly lower
with iodixanol in patients with severe renal impairment (p  0.023) or concomitant diabetes
(p  0.041), or in patients given 140 ml of contrast media (p  0.038). Multivariate
analysis identified use of ioxaglate (OR 2.65, 95% CI 1.11 to 6.33, p  0.028), baseline SCr,
mg/dl (OR 2.0, 95% CI 1.04 to 3.85, p 0.038), and left ventricular ejection fraction, % (OR
0.97, 95% CI 0.94 to 0.99, p  0.019) as independent risk factors for CIN.
CONCLUSIONS The IOCM iodixanol was significantly less nephrotoxic than ioxaglate, an ionic, dimeric
LOCM. (The RECOVER Trial; http://clinicaltrials.gov; NCT00247325) (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.047Cardiol 2006;48:924–30) © 2006 by the American College of Cardiology Foundation
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iontrast-induced nephropathy (CIN) is usually defined as
n acute decline in renal function, expressed as a relative
ncrease in serum creatinine (SCr) concentration of at least
5% or an absolute increase in SCr of 0.5 mg/dl (44.2
mol/l) in the absence of other etiologies (1). Contrast-
nduced nephropathy is a significant problem in clinical
ractice, but also one that is often unrecognized. At 12% of
ases, it is the third leading cause of hospital-acquired acute
enal failure (2) and is associated with 36% mortality in
atients who require in-hospital dialysis with 19% survival
t 2 years (3,4). When there are no risk factors, the incidence
From the *Division of Cardiology and the †Division of Nephrology, Department
f Internal Medicine, Seoul National University College of Medicine/Cardiovascular
enter, Seoul National University Hospital, Seoul, Korea; and the ‡Cardiovascular
enter, Dongguk University International Hospital, Goyang-si, Gyeonggi-do, Korea.
his study was supported by a grant from the clinical research center for ischemic
eart disease sponsored by the Ministry of Health and Welfare, Republic of Korea
0412-CR02-0704-0001). Drs. Jo and Youn contributed equally to this work.l
Manuscript received April 17, 2006; revised manuscript received June 1, 2006,
ccepted June 26, 2006.f CIN is low, 5% (5). However, patients increasingly
ncountered in interventional cardiology practice have multiple
isk factors for CIN, such as renal impairment (with and
ithout diabetes), congestive heart failure, reduced arterial
olume, and concurrent use of nephrotoxic medications, and in
uch patients the incidence of CIN has been reported to range
etween 11% and 50% (6,7).
Certain procedural variables can also increase the risk of
IN in patients undergoing coronary angiography with or
ithout percutaneous coronary intervention (PCI); these
nclude use of an intra-aortic balloon pump (8), contrast
edia dose (3,8–10), and the type of contrast medium used
7,11–15). Low-osmolar contrast media (LOCMs) have
een associated with a significantly lower incidence of CIN
n patients with renal impairment compared with high-
smolar contrast media (HOCMs) in numerous studies and
n a meta-analysis of 31 trials (7,11–13).
The large body of clinical data showing that LOCMs areess nephrotoxic than HOCMs is consistent with the
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September 5, 2006:924–30 The RECOVER Study: Iodixanol vs. Ioxaglate in CINypothesis that contrast hyperosmolality contributes to the
ephrotoxicity of contrast media. Because LOCMs are
yperosmolar to plasma, it has been suggested that iso-
smolar contrast media (IOCM), which are iso-osmolar to
lasma, may be even less nephrotoxic than LOCMs. Two
rospective, randomized, controlled trials comparing the
enal effects of the nonionic, dimeric, IOCM iodixanol and
he nonionic, monomeric, LOCM iohexol, one in patients
ndergoing renal and/or peripheral angiography and the
ther in patients undergoing coronary and/or aortofemoral
ngiography, have shown that iodixanol is significantly less
ephrotoxic than the nonionic, monomeric LOCM iohexol
14,15). However, clinical studies are needed to compare the
enal effects of iodixanol with those of other LOCMs, i.e.,
onic and dimeric, to confirm that contrast hyperosmolality
s the main cause of CIN rather than other physicochemical
roperties such as viscosity or ionicity.
In this article, we report the results of a randomized,
rospective, controlled, single-center trial that compared
he nephrotoxicity of the nonionic, dimeric, IOCM iodixa-
ol with the ionic, dimeric, LOCM ioxaglate in patients
ith renal insufficiency undergoing coronary angiography
ith or without PCI.
ETHODS AND PATIENTS
ethods. The RECOVER (Renal Toxicity Evaluation
nd Comparison Between Visipaque and Hexabrix in Pa-
ients With Renal Insufficiency Undergoing Coronary An-
iography) study compared the nephrotoxicity of iodixanol
nd ioxaglate used as contrast media in patients undergoing
oronary angiography with or without PCI. Both patients
nd investigators were blinded regarding study group as-
ignment. Patients were randomized by the permuted block
andomization method to receive iodixanol or ioxaglate.
oronary angiography was performed according to standard
rotocols for our center using the radial or femoral ap-
roach. Patients received intravenous half-isotonic saline at
rate of 1 ml/kg/h at least 8 h before and after coronary
ngiography. The SCr was measured in the morning on the
ay before coronary angiography (day 1) before the start
f pre-hydration and on days 1 and 2 after the procedure.
Abbreviations and Acronyms
CI  confidence interval
CIN  contrast-induced nephropathy
CM  contrast medium
CrCl  creatinine clearance
HOCM  high-osmolar contrast medium
IOCM  iso-osmolar contrast medium
LOCM  low-osmolar contrast medium
LVEF  left ventricular ejection fraction
OR  odds ratio
PCI  percutaneous coronary intervention
SCr  serum creatininehe highest SCr on day 1 or day 2 was used to calculate the vhange in SCr. All SCr levels were determined in a blinded
ashion by laboratory personnel who measured it by autoana-
yzer in the Department of Laboratory Medicine in Seoul
ational University Hospital. The Cockcroft-Gault formula
as used to calculate creatinine clearance (CrCl) (16).
The primary end point was the incidence of CIN, defined
s a relative increase in SCr from baseline of 25% or an
bsolute increase of 0.5 mg/dl (44.2 mol/l) during
ays 1 and 2. Secondary end points included the proportion
f patients showing an increase in SCr of 0.5 mg/dl
44.2 mol/l), the proportion with a 1.0 mg/dl (88.4
mol/l) increase in SCr, and the mean peak increase in SCr.
n addition, data were subanalyzed according to the pres-
nce of severe renal impairment (defined as baseline CrCl
30 ml/min), concomitant diabetes, the use of 140 ml
ontrast media, low left ventricular systolic function (left
entricular ejection fraction [LVEF] by echocardiography
40%), and patient age (75 vs. 75 years). Risk factors
or CIN were determined.
Adverse events occurring during hospitalization and dur-
ng 1 month after hospitalization were recorded. A com-
osite safety end point (death, myocardial infarction, revas-
ularization, cerebral infarction, dialysis after contrast
rocedure) was analyzed.
atients. Patients referred to the Cardiovascular Center at
eoul National University Hospital, Seoul, Korea, for cor-
nary angiography with or without PCI were screened from
anuary 2004 through December 2004. Patients age 19
ears with CrCl rates 60 ml/min (1 ml/s) using the
ockcroft-Gault formula were considered to be eligible
16). Exclusion criteria were pregnancy, lactation, having
eceived contrast media within 7 days of study entry,
mergent coronary angiography, acute renal failure, end-
tage renal disease requiring dialysis, history of hypersensi-
ivity reaction to contrast media, cardiogenic shock, pulmo-
ary edema, multiple myeloma, mechanical ventilation,
arenteral use of diuretics, use of N-acetylcysteine, and use
f metformin or nonsteroidal anti-inflammatory drugs
ithin 48 h of the procedure. The protocol was approved by
he Institutional Review Board at our institution. All
atients provided informed, written consent.
tatistical analysis. For calculation of the sample size, a
0% incidence of CIN for the ioxaglate group and an 8%
ncidence for the iodixanol group (corresponding to a 60%
ifference between the 2 groups) were assumed (17–19).
sing this assumption, a sample size of 128 patients per
roup would permit a 2-sided significance level of 5% and
0% power. To allow for the possibility of patients lost
uring follow-up, incomplete data collection, and protocol
iolations, the planned sample size was 150 patients in each
roup.
Data were analyzed from the per-protocol population. All
ata are presented as percentages or as mean  standard
eviation. Comparisons of baseline data were performed
sing the chi-square test or Fisher exact test (categorical
ariables) and the Student t test (continuous variables).
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The RECOVER Study: Iodixanol vs. Ioxaglate in CIN September 5, 2006:924–30nivariate and multivariate logistic regression analysis were
erformed using all potentially relevant variables. All p
alues 0.05 were considered statistically significant. Sta-
istical analyses were performed using SPSS software ver-
ion 13.0 (SPSS Inc., Chicago, Illinois).
The authors had full access to the data and take respon-
ibility for its integrity. All authors have read and agree to
he manuscript as written.
ESULTS
atient demographics and disposition. Between January
004 and December 2004, of a total of 2,474 consecutive
atients screened, 300 were randomized to receive iodixanol
n  151) or ioxaglate (n  149). After exclusions because
f protocol violations, incomplete laboratory test results, and
nsufficient follow-up, 140 patients receiving iodixanol and
35 patients receiving ioxaglate were included in the per-
rotocol analysis (Fig. 1). Demographic and baseline data
re provided in Table 1. The patient groups did not differ
Figure 1. Flow of paignificantly with the exception of age. wrimary end point—the incidence of CIN. Eleven pa-
ients in the iodixanol group (7.9%) and 23 patients in the
oxaglate group (17.0%) had an increase in SCr from
aseline of 25% or 0.5 mg/dl (44.2 mol/l) within 2
ays of contrast media administration (p  0.021) (Fig. 2).
he odds ratio (OR) for CIN according to this definition
or the iodixanol group (using the ioxaglate group data as
eference) was 0.415 (95% confidence interval [CI] 0.194 to
.889).
The incidence of increases in SCr from baseline of 0.5
g/dl (44.2 mol/l) and 1.0 mg/dl (88.4 mol/l)
ere also analyzed. Fewer patients in the iodixanol group (5;
.6%) showed an increase of 0.5 mg/dl (44.2 mol/l)
ompared with the ioxaglate group (12; 8.9%), but this
ifference did not reach statistical significance (p  0.067).
wo patients in the iodixanol group (1.4%) and 6 in the
oxaglate group (4.4%) had an increase in SCr from baseline
f 1.0 mg/dl (88.4 mol/l), but the difference was not
ignificant (p  0.167).
ubgroup analyses. The incidence of CIN among patients
through the study.ith severe renal impairment was significantly lower for
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September 5, 2006:924–30 The RECOVER Study: Iodixanol vs. Ioxaglate in CINatients receiving iodixanol (2 of 16 patients; 12.5%) com-
ared with that for patients receiving ioxaglate (8 of 15
atients; 53.3%) (p  0.023). Similarly, the incidence of
IN was significantly lower for diabetic patients in the
odixanol group (5 of 48 patients; 10.4%) compared with
hat for diabetic patients in the ioxaglate group (13 of 49
atients; 26.5%) (p  0.041). In patients who received
140 ml of contrast medium, the incidence of CIN in the
odixanol group (8 of 82 patients; 9.8%) was significantly
ower than in the ioxaglate group (19 of 89 patients; 21.3%)
igure 2. Incidence of contrast-induced nephropathy according to 3
Table 1. Clinical, Biochemical, and Procedural
Analysis
Characteristic Iodixano
Age, yrs 66.1
Gender, male/female 79
Weight, kg* 59.70
BMI, kg/m2* 23.45
LVEF, %* 55.2
Diabetes mellitus, n (%) 48
Hypertension, n (%) 73
Dyslipidemia, n (%) 40
Current smoker, n (%) 18
Serum creatinine‡
Baseline level, mg/dl* 1.38
Baseline level 1.4 mg/dl, n (%) 54
Baseline CrCl, ml/min* 45.2
Medications, n (% of patients)
ACEI or ARB 50
Nitrate 53
Calcium channel blocker 31
Beta-blocker 44
Statin 32
PCI performed, n (%) 62
Contrast media administration
Contrast agent dose, ml* 204.6
Dose 140 ml, % (n/N) 64.1 (
*Values are mean  standard deviation. †All p values derived
to micromoles per liter, multiply by 88.4. To convert values
ACEI  angiotensin-converting enzyme inhibitor; ARB
creatinine clearance; LVEF  left ventricular ejection fractio2
efinitions for patients receiving iodixanol and ioxaglate as contrast media
or coronary angiography. SCr  serum creatinine.p  0.038). In patients with mildly depressed or preserved
VEF (EF40%), CIN was significantly less frequent with
odixanol (6 of 115 patients; 5.2%) compared with ioxaglate
17 of 113 patients; 15.0%) (p 0.014), but in patients with
oderately or severely depressed LVEF (EF 40%), the
requency of CIN did not differ between iodixanol (5 of 21
atients; 23.8%) and ioxaglate (5 of 20 patients; 25.0%) (p
1.0). Finally, in patients75 years, the incidence of CIN
as significantly lower in iodixanol patients (9 of 115
atients; 7.8%) compared with ioxaglate patients (18 of 105
atients; 17.1%) (p  0.035). In patients 75 years, the
ncidence of CIN was not different between the contrast
edia (Table 2).
isk factors for CIN. Univariate analysis was performed to
dentify baseline and procedural risk factors for development
f CIN. Baseline risk factors associated with CIN in the
tudy patients included hypertension (defined as systolic
ressure 140 mm Hg or diastolic pressure 90 mm Hg)
p  0.008), diabetes (p  0.024), dyslipidemia (defined as
otal cholesterol level 240 mg/dl or patients who have
aken statins) (p  0.028), basal SCr (continuous variable)
p  0.007), and left ventricular systolic function (contin-
ous variable) (p  0.002). Age was not a risk factor by
nivariate analysis. Procedural variables associated with
IN were dose of contrast media used (continuous variable)
p  0.048) and use of ioxaglate (p  0.024).
Multivariate analysis identified 3 risk factors for the
evelopment of CIN in study patients: use of ioxaglate (OR
racteristics of Patients in the Per-Protocol
140) Ioxaglate (n  135) p Value†
68.7  7.5 0.010
75/60 0.884
5 59.38  9.53 0.778
0 23.40  3.00 0.899
.2 54.4  13.1 0.619
49 (36.3) 0.727
77 (57.0) 0.415
44 (32.6) 0.469
14 (10.4) 0.520
6 1.30  0.50 0.229
41 (30.4) 0.153
.4 44.9  10.3 0.811
48 (35.6) 0.978
49 (36.3) 0.789
23 (17.0) 0.287
44 (32.6) 0.836
37 (27.4) 0.384
51 (37.8) 0.273
9.2 194.8  123.9 0.582
8) 69.0 (89/129) 0.402
the chi-square test. ‡To convert values for serum creatinine
rCl to ml/s, multiply by 0.01667.
iotensin receptor blocker; BMI  body mass index; CrCl 
I  percutaneous coronary intervention.Cha
l (n 
 8.6
/61
 9.3
 2.9
 13
(34.3)
(52.1)
(28.6)
(12.9)
 0.5
(38.6)
 11
(35.7)
(37.9)
(22.1)
(31.4)
(22.9)
(44.3)
 15
82/12
from
for C.65; 95% CI 1.11 to 6.33; p  0.028), baseline SCr, mg/dl
(
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OR 0.97; 95% CI 0.94 to 0.99; p  0.019).
bsolute peak increase in SCr and incidence of acute
enal failure requiring dialysis. For patients receiving
odixanol, mean SCr increased from the baseline level of
.38  0.56 mg/dl (121.9  49.5 mol/l) to a peak of 1.40
0.63 mg/dl (123.8  55.7 mol/l) within 2 days of the
ontrast procedure; this change was not significant (p 
.288). However, for patients receiving ioxaglate, mean SCr
ncreased significantly from a baseline level of 1.30  0.50
g/dl (114.9  44.2 mol/l) to a peak of 1.44  0.79
g/dl (127.3  69.8 mol/l) (p  0.001) (Fig. 3). The
odixanol group showed a significantly smaller mean in-
rease in SCr compared with the ioxaglate group (0.024 
.26 vs. 0.144  0.50 mg/dl; p  0.015). The overall peak
Cr was observed on day 1 in 42.2%, on day 2 in 34.9%, and
qual value on both days in 22.9% of all patients. In patients
ith CIN, the peak SCr level was observed mainly on day 2
able 2. Subgroup Analysis of Differences in the Incidence of
ontrast-Induced Nephropathy Between Iodixanol and Ioxaglate
Subgroups Iodixanol Ioxaglate p Value
rCl 30 ml/min, n 16 15
Basal SCr (SD) 2.52 (0.65) 2.11 (0.77) 0.118
CIN, n (%) 2 (12.5) 8 (53.3) 0.023§
rCl 30 ml/min, n 124 120
Basal SCr (SD)* 1.23 (0.33) 1.20 (0.35) 0.479
CIN, n (%) 9 (7.3) 15 (12.5) 0.169
iabetes, n 48 49
Basal SCr (SD) 1.49 (0.61) 1.45 (0.54) 0.742
CIN, n (%) 5 (10.4) 13 (26.5) 0.041
on-diabetes, n 92 86
Basal SCr (SD) 1.32 (0.53) 1.21 (0.46) 0.159
CIN, n (%) 6 (6.5) 10 (11.6) 0.234
ose of CM 140 ml, n 82† 89†
Basal SCr (SD) 1.33 (0.48) 1.30 (0.50) 0.769
CIN, n (%) 8 (9.8) 19 (21.3) 0.038
ose of CM 140 ml, n 46† 40†
Basal SCr (SD) 1.48 (0.66) 1.30 (0.52) 0.145
CIN, n (%) 2 (4.3) 4 (10.0) 0.410§
VEF 40%, n 115‡ 113‡
Basal SCr (SD) 1.33 (0.53) 1.27 (0.46) 0.339
CIN, n (%) 6 (5.2) 17 (15.0) 0.014
VEF 40%, n 21‡ 20‡
Basal SCr (SD) 1.63 (0.69) 1.45 (0.69) 0.390
CIN, n (%) 5 (23.8) 5 (25.0) 1.0§
ge 75 yrs old, n 25 30
Basal SCr (SD) 1.16 (0.27) 1.17 (0.36) 0.873
CIN, n (%) 2 (8) 5 (16.7) 0.436§
ge 75 yrs old, n 115 105
Basal SCr (SD) 1.42 (0.59) 1.34 (0.53) 0.248
CIN, n (%) 9 (7.8) 18 (17.1) 0.035
Basal serum creatinine in milligrams per deciliter is given as mean and standard
eviation. To convert values for creatinine to micromoles per liter, multiply by 88.4.
The sum of the 4 groups did not meet the total N of 275 because some patients had
o data for the amount of contrast media used. ‡The sum of the 4 groups did not meet
he total N of 275 because some patients did not receive the echocardiography. §p
alue derived from Fisher exact test.
CIN  contrast-induced nephropathy; CM  contrast media; NS  not
ignificant; SCr  serum creatinine; SD  standard deviation; other abbreviations as
n Table 1.22 of 34 patients; 64.7%), but in patients in whom CIN did dot occur, it was observed mainly on day 1 (106 of 241
atients; 44.0%).
Two patients developed acute renal failure requiring
emodialysis: 1 patient in the iodixanol group and 1 in the
oxaglate group. Both patients returned to their basal levels
f renal function before hospital discharge, but several
onths later required hemodialysis, which was unrelated to
n-study coronary angiography.
omposite safety end point. There was no difference
etween the groups in terms of the composite safety end
oint (death, myocardial infarction, revascularization, cere-
ral infarction, dialysis after contrast procedure) in the
odixanol group (3 of 140 patients; 2.1%) and the ioxaglate
roup (3 of 135 patients; 2.2%).
ISCUSSION
o our knowledge this is the first study to compare the
ephrotoxicity of iodixanol, a nonionic dimeric IOCM,
ith ioxaglate, an ionic dimeric LOCM. We found that in
atients with renal impairment, iodixanol was associated
ith a significantly lower incidence of CIN than ioxaglate.
he incidence of CIN was also significantly lower with
odixanol in those patients with severe renal impairment
baseline CrCl 30 ml/min), those with concomitant dia-
etes, those who received 140 ml of contrast, those with
VEF 40%, and age 75 years. In multivariate analysis,
se of ioxaglate was an independent risk factor for CIN.
A large body of clinical data has shown that LOCMs are
ssociated with a lower incidence of CIN compared with
OCMs in patients with renal impairment (7,11–13). The
ncidence of CIN associated with iodixanol in high-risk pa-
ients has previously been shown to be significantly lower than
hat with iohexol, a nonionic, monomeric LOCM in 2 studies.
halmers and Jackson (14) conducted a prospective, single-
enter, randomized, unblinded trial in which 124 patients with
Cr1.7 mg/dl, 34 of whom had diabetes, received iodixanol
nd iohexol during renal and/or peripheral angiography. A
ignificantly smaller proportion of patients receiving iodixanol
ad an increase in SCr 10% compared with those receiving
ohexol (15% vs. 31%; p  0.05), and a lower proportion of
atients in the iodixanol group had a 25% increase in SCr
han those in the iohexol group (3.7% vs. 10%; p  NS) (14).
spelin et al. (15) confirmed these results in a prospective,
ulticenter, double-blind trial (NEPHRIC [Nephrotoxicity in
igh-Risk Patients Study of Iso-Osmolar and Low-Osmolar
on-Ionic Contrast Media]) comparing the nephrotoxicity of
odixanol and iohexol in 129 diabetic patients with SCr
etween 1.5 (132.6 mol/l) and 3.5 mg/dl (309.4 mol/l)
ndergoing coronary or aortofemoral angiography. The inci-
ence of CIN (defined as a0.5 mg/dl [44.2 mol/l] increase
n SCr) was significantly lower in the iodixanol group com-
ared with the iohexol group (3% vs. 26%; p  0.002) (15).
Like iohexol, ioxaglate is a LOCM; however, although
ohexol is nonionic and monomeric, ioxaglate is ionic and
imeric. The finding that iodixanol is less nephrotoxic than
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ontrast osmolality, rather than viscosity or ionicity, is an
mportant factor in CIN.
Osmolality is a useful characteristic for classifying iodinated
ontrast media. The older, high-osmolar agents such as dia-
rizoate are very hyperosmolar (7 times that of blood). The
o-called LOCM are still considerably hyperosmolar (2 to 3
imes that of blood) (17), and iodixanol is the only iodinated
ontrast agent not hyperosmolar to blood. Experimental stud-
es investigating the role of osmolality in the pathogenesis of
IN have produced conflicting results (20–22), but as noted
bove, evidence from prospective, randomized clinical trials
uggests an association between CIN and contrast osmolality
ather than between CIN and contrast viscosity, ionicity, or
hemotoxicity. To date, there is no high-quality clinical evi-
ence from prospective, randomized, controlled clinical trials
o support the notion that contrast viscosity causes CIN.
In our study the patients receiving ioxaglate were 2.5
ears older on average than the patients receiving iodixanol,
nd the difference was significant (p  0.010). In some
tudies, advanced age has been reported to increase the risk
f CIN (8), but the difference between the iodixanol and
oxaglate groups is likely to be too small to be relevant to the
reater incidence of CIN in the ioxaglate group. Moreover,
n the univariate and multivariate analyses, age was not a
isk factor for CIN (p  0.835, 95% CI 0.910 to 1.079).
urthermore, the iodixanol and ioxaglate groups did not
iffer significantly with respect to baseline renal function as
videnced by both mean SCr and mean CrCl, and the
roportion of patients with diabetes and other demographic
nd baseline parameters was similar, indicating that the
odixanol and ioxaglate patient groups had comparable risk
or CIN at the start of the trial. Patients in both groups
ollowed the same hydration protocol as other clinical trials,
lthough recently it was reported that isotonic saline given
igure 3. Changes in SCr concentration (baseline to peak) after contrast a
ithin 48 h after contrast administration are shown for each patient in the
ymbols illustrate the mean ( SD) baseline and peak SCr values for the 2
nd peak SCr for iodixanol and ioxaglate, respectively. See text for additio
8.4. mOsm/kg  milliosmoles per 1,000 grams; mPa·s  millipascal secor 12 h before and after the administration of contrast oedia might be more effective in preventing CIN than the
alf-isotonic saline used in our study (23).
In the subgroups of patients with more severe renal
nsufficiency and with diabetes, iodixanol was less likely to
ause CIN than ioxaglate. Specifically, in patients with
evere renal impairment (CrCl 30 ml/min), ioxaglate was
ssociated with a significantly higher (4 times) incidence of
IN than iodixanol (p  0.023). In diabetic patients with
enal dysfunction (CrCl 60 ml/min), the incidence of
IN was also significantly higher (2.5 times) with ioxaglate
han iodixanol (p  0.041) (Table 2). Based on these
ndings, iodixanol seems to offer greater clinical benefit
han ioxaglate in renally compromised, sicker populations
or whom the risk of CIN and its associated morbidity and
ortality are known to be highest (3,6,8,9,24). This sup-
orts and extends the findings of the NEPHRIC study,
hich also showed that iodixanol led to a greater reduction
n the incidence of CIN compared with the nonionic
OCM iohexol in a high-risk population of patients with
oth diabetes and renal impairment (15). With the aging
opulation and the incidence of diabetes increasing, older
nd sicker patients with serious renal and cardiovascular
omorbidities now comprise a large proportion of those
ndergoing coronary angiography. Given this trend, the
pparent clinical benefit shown for iodixanol versus ioxag-
ate here has important implications not only in terms of the
otential for improved patient outcomes but also in terms of
he potential for reduced health care costs in populations
hat traditionally have been associated with longer hospital
tays and greater use of health care resources (25,26).
In patients given greater doses of contrast media, iodixa-
ol was also less likely to cause CIN than ioxaglate. In the
ubgroup of patients with more severely depressed LVEF,
e could not detect a difference in CIN between the 2
ontrast media (23.8% vs. 25%, p  1.0), but in the group
istration for coronary angiography. Baseline and peak SCr concentrations
nol (n  140) and ioxaglate (n  135) study arms. The vertical lines and
s as described in the text; p values refer to the difference between baseline
tails. To convert values for creatinine to micromoles per liter, multiply by
SCr  serum creatinine; SD  standard deviation.dmin
iodixa
groupf mildly depressed or preserved LVEF (40%), iodixanol
h
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esult might suggest that in patients with severely depressed
VEF, the left ventricular systolic function itself plays a
ore significant role than the type of contrast media in the
ccurrence of CIN (Table 2). Although we observed a lower
ncidence of CIN with iodixanol than with ioxaglate in
atients aged 75 years, the fact that there is only a trend
n favor of iodixanol in patients 75 years is probably
ttributable to the small sample size in this patient subset.
In the present study, we did not observe any significant
ifference between iodixanol and ioxaglate in a composite end
oint of several serious adverse events (death, myocardial
nfarction, revascularization, cerebral infarction, dialysis after
ontrast procedure) during a 30-day follow-up. This study was
ot sufficiently powered to fully evaluate the incidence of
erious adverse events, and the follow-up period of 30 days
oes not provide data on long-term sequelae after iodixanol
nd ioxaglate administration. Ionic contrast media such as
oxaglate have greater anticoagulant properties than nonionic
ontrast media such as iodixanol in vitro (27,28). To date,
owever, this difference has not been linked to a greater
ncidence of major cardiovascular adverse events with iodixa-
ol, relative to ioxaglate, in clinical trials involving both
igh-risk (29) or lower-risk (30) cardiac populations.
The finding of reduced nephrotoxicity with iodixanol in
his and other studies is clinically important because of the
ssociation of CIN with longer hospitalization, delayed
reatments and procedures, and greater short-term and
ong-term morbidity and mortality. Data from large, long-
erm trials are needed to confirm a correlation between
eduction in the incidence of CIN and further benefits of
OCM in high-risk patients.
In conclusion, iodixanol, a nonionic, dimeric IOCM, was
ssociated with a significantly lower incidence of CIN than
oxaglate, an ionic, dimeric LOCM in patients with renal
mpairment as well as a subgroup of diabetes or patients
eceiving a high dose of contrast media.
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